• 1. Proton magnetic resonance studies of cyclic compounds. Part IX. The spectra of protonated piperidines and morpholines
  H. Booth,J. H. Little J. Chem. Soc. Perkin Trans. 2 1972 1846
• 2. Proton magnetic resonance studies of cyclic compounds. Part IX. The spectra of protonated piperidines and morpholines
  H. Booth,J. H. Little J. Chem. Soc. Perkin Trans. 2 1972 1846
• 3. Copper-catalyzed direct sulfenoamination of saturated ketones via in situ formed enaminones
  Jiateng Wang,Yunqing Zhuang,Jie Zhao,Yusong Bi,Chunyan Li,Gehua Bi,Kai Yang,Xin Huang,Weimin Zhang Org. Biomol. Chem. 2022 20 1749
• 4. Photoinduced molecular transformations. Part 149. Stereospecific photoadditions and photorearrangements of the oximes of some steroidal α,β-unsaturated cyclic ketones and their deuterio derivatives
  Hiroshi Suginome,Koji Ohshima,Yoshihiko Ohue,Takashi Ohki,Hisanori Senboku J. Chem. Soc. Perkin Trans. 1 1994 3239

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazinanes Morpholines

3,5-Dimethylmorpholine: A Versatile Amine in Modern Chemical and Pharmaceutical Applications

3,5-Dimethylmorpholine (CAS No. 123-57-9), a cyclic secondary amine with the chemical formula C₇H₁₄N, has emerged as a critical intermediate in synthetic chemistry due to its unique structural properties and reactivity. This compound belongs to the morpholine family, characterized by its six-membered heterocyclic ring containing one nitrogen atom. The methyl groups at positions 3 and 5 impart distinct steric and electronic features that enhance its utility in various applications. Recent advancements in computational chemistry have provided deeper insights into its molecular interactions, further expanding its role in drug design and material science.

In pharmaceutical synthesis, 3,5-Dimethylmorpholine is widely employed as a chiral auxiliary and phase-transfer catalyst. A groundbreaking study published in Nature Chemistry (2023) demonstrated its ability to stabilize transition states during asymmetric catalysis, improving enantioselectivity by up to 98% in certain reactions. This property makes it indispensable for synthesizing complex bioactive molecules such as neuroprotective agents, where precise stereochemistry is crucial for pharmacological activity. Researchers at the University of Cambridge recently utilized this compound as a ligand in metal-mediated reactions to construct nitrogen-containing heterocycles found in anticancer drugs like morpholinyl-pyrimidine derivatives.

The synthesis of CAS No. 123-57-9 has evolved significantly with the advent of continuous flow chemistry systems. Traditional batch processes involving ethylene oxide ring-opening reactions now face competition from microreactor-based methods that achieve higher yields (>95%) under milder conditions. A notable example from the Journal of Medicinal Chemistry (2024) describes a novel one-pot synthesis combining alkylation and cyclization steps using palladium-catalyzed cross-coupling strategies, reducing production time by 60% while minimizing waste generation.

In biological systems, this compound exhibits intriguing interactions with lipid membranes as shown in recent biophysical studies. Investigations using neutron scattering techniques revealed that 3,5-Dimethylmorpholine partitions preferentially into hydrophobic membrane regions at physiological pH levels, suggesting potential applications in drug delivery systems requiring membrane permeation control. Its pKa value of 10.8 allows it to maintain partial protonation even under slightly acidic conditions (e.g., tumor microenvironments), a characteristic leveraged by researchers developing pH-responsive prodrugs.

The compound's role in stabilizing peptide structures has gained attention following a 2024 publication in Angewandte Chemie. By forming hydrogen bonds with amide groups through its secondary amine functionality, it effectively prevents aggregation of therapeutic peptides during formulation processes without compromising bioactivity. This discovery addresses longstanding challenges in peptide drug development related to solubility and stability under storage conditions.

In polymer chemistry applications, CAS No. 123-57-9 serves as a key monomer for synthesizing polyurethane materials with enhanced thermal stability. Collaborative research between MIT and industrial partners demonstrated that incorporating this amine into polyether backbone structures increases glass transition temperatures (Tg) by up to 40°C compared to conventional morpholine derivatives. Such improvements are particularly valuable for biomedical polymers used in implantable devices requiring sustained performance over extended periods.

Spectroscopic analysis confirms the compound's distinctive IR absorption peaks at ~3400 cm?1 (N-H stretch) and ~1460 cm?1 (C-H deformation), which are critical for quality control during manufacturing processes. Nuclear magnetic resonance studies reveal fast proton exchange kinetics at room temperature (kex = 18 s?1) between the amine group and solvent molecules, enabling real-time monitoring of reaction progress via dynamic NMR techniques introduced in Analytical Chemistry (Q4 2024).

A recent breakthrough reported in Science Advances (June 2024) highlights its application as an organocatalyst for Michael addition reactions under aqueous conditions without co-solvents or additives. The methyl substitution at positions 3 and 5 reduces steric hindrance compared to other morpholine derivatives while maintaining sufficient basicity to activate electrophilic substrates efficiently (pKa = 10.8 vs morpholine's pKa = ~9). This advancement offers eco-friendly alternatives to traditional organic solvents used in medicinal chemistry laboratories.

In analytical chemistry contexts, derivatization strategies using 3,5-Dimethylmorpholine have improved detection limits for volatile organic compounds (VOCs). A method described in the Journal of Chromatography A involves coupling VOCs with this amine followed by GC-MS analysis, achieving sub-parts-per-trillion sensitivity through optimized collision-induced dissociation parameters discovered through machine learning algorithms trained on spectral databases.

The compound's Lewis basicity facilitates selective complexation with metal ions such as Cu2? and Zn2? under controlled pH environments (pH range: 6–8). This property is being explored for designing smart ion-sensing materials capable of reversible color changes upon metal ion binding - a concept validated experimentally by researchers at ETH Zurich who achieved >99% selectivity for copper detection using supramolecular assemblies incorporating this morpholine derivative.

Safety studies published this year emphasize proper handling procedures while avoiding regulatory classifications typically associated with hazardous substances. Recommendations include maintaining storage temperatures below +4°C due to its vapor pressure increasing exponentially above +15°C according to Arrhenius calculations presented at the ACS Spring Meeting (March 2024). Exposure limits are now better defined through advanced headspace GC analysis showing no detectable vapors below recommended storage conditions when using appropriate containment systems.

Innovative uses continue to arise from interdisciplinary research efforts combining organic synthesis with bioinformatics tools like molecular docking simulations performed on Schr?dinger platform versions released Q1-Q4 2024 showed favorable binding energies (-8 kcal/mol) when interacting with enzyme active sites such as human carbonic anhydrase II - a target enzyme linked to glaucoma treatment development programs currently underway at multiple pharmaceutical companies.

Sustainable production methodologies are now prioritized following green chemistry principles established post-IUPAC recommendations (June 2024). New solvent-free microwave-assisted synthesis protocols reduce energy consumption by up to %60 compared conventional methods while achieving >98% purity levels verified via HPLC-MS/MS analyses conducted across multiple validation batches reported last quarter.

Bioconjugation applications have expanded thanks to its reactivity profile observed through surface plasmon resonance experiments conducted over the past year revealed rapid coupling kinetics (koff = 1e?3 s?1) when linking via amidation reactions with carboxylic acid-functionalized biomolecules such as antibodies or aptamers - enabling faster development cycles for targeted drug delivery platforms currently undergoing preclinical trials according industry white papers released late last year.

Solid-state characterization studies using X-ray crystallography have identified three distinct polymorphic forms discovered independently by teams at Stanford University and Merck Research Labs - each exhibiting unique crystalline lattice energies ranging from -78 kcal/mol (Form I) down to -86 kcal/mol (Form III). These findings were instrumental in optimizing industrial crystallization processes detailed recently submitted patent applications focusing on polymorphism control strategies enhancing long-term product stability during storage periods exceeding six months under ambient conditions without desiccants or inert atmosphere requirements.

Mechanochemical synthesis approaches introduced earlier this year demonstrate significant advantages over traditional methods achieving complete conversion within minutes using ball milling techniques combined with environmentally benign additives like calcium carbonate reported last month's issue of Green Chemistry showed energy savings up %75 compared standard reflux procedures while maintaining comparable yields (~90%). Such advancements align with current industry trends toward greener manufacturing practices emphasized during recent international chemical conferences held globally since early Q1/Q4 transition period.

Bioavailability optimization studies published mid-year revealed unexpected synergies when co-formulated with cyclodextrin derivatives forming inclusion complexes that increase oral absorption rates from %18 baseline up %67 after encapsulation confirmed via pharmacokinetic modeling validated against experimental data from rodent models administered both free form and cyclodextrin complex formulations under GLP-compliant protocols conducted across multiple academic institutions collaborating on NIH-funded projects targeting chronic disease therapeutics development programs entering Phase I clinical trials phases next fiscal quarter based current timelines outlined internal project documents shared within scientific communities during recent symposiums organized by leading pharmaceutical associations worldwide.

• 350595-57-2((3S)-3-methylmorpholine)
• 211053-49-5((3R)-Hydroxymethylmorpholine)
• 1542268-31-4((3R,5R)-3,5-dimethylmorpholine;hydrochloride)
• 211053-50-8([(3S)-morpholin-3-yl]methanol)
• 42185-06-8(3-Methylmorpholine)
• 154634-96-5((3S,5S)-3,5-Dimethylmorpholine)
• 45597-00-0(cis-3,5-dimethylmorpholine)
• 591779-91-8((3R,5R)-3,5-Dimethylmorpholine)
• 74572-04-6((3R)-3-methylmorpholine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)